{"disease":{"id":"polyarticular-juvenile-idiopathic-arthritis-pjia","name":"polyarticular juvenile idiopathic arthritis pjia"},"drugs":{"marketed":[{"drug_id":"tocilizumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis (PJIA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"tofacitinib-xeljanz","indication_name":"Polyarticular Juvenile Idiopathic Arthritis (pJIA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tofacitinib (Xeljanz)","generic_name":"tofacitinib-xeljanz","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK3","drug_class":"Janus Kinase Inhibitor","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}